Devices and Methods for Treating Occlusion of the Ophthalmic Artery
20170202574 ยท 2017-07-20
Inventors
Cpc classification
A61B3/16
HUMAN NECESSITIES
A61F9/00736
HUMAN NECESSITIES
A61B17/221
HUMAN NECESSITIES
A61B17/320725
HUMAN NECESSITIES
A61F2/013
HUMAN NECESSITIES
A61B17/12022
HUMAN NECESSITIES
A61F9/00781
HUMAN NECESSITIES
A61F2002/018
HUMAN NECESSITIES
International classification
A61B17/3207
HUMAN NECESSITIES
A61B17/221
HUMAN NECESSITIES
Abstract
There is provided herein a disclosure and specification of invention(s) relating to devices and methods for percutaneous access and treatment of vascular structures in the rear of the eye, including treatment for the symptoms related to Wet Age Related Macular Degeneration by removal of stenosis of the OA, thereby restoring normal, or near normal, blood flow to the rear of the eye, including the retina and associated structures. Also provided herein is a disclosure and specification of invention(s) relating to methods and devices for selective manipulation of Intraocular Pressure (IOP) be means of mechanical force for the purpose of inducing retrograde flow in the ophthalmic vasculature.
Claims
1) An apparatus for treating obstruction of the ophthalmic artery, comprising an IOP device for mechanically applying a force against the front of the eye to increase Intraocular Pressure (IOP) sufficient to temporarily stop antegrade blood flow in the ophthalmic vasculature at the back of the eye and thereby induce retrograde flow in the ophthalmic vasculature; an atherectomy kit for performing an atherectomy upon the ophthalmic artery of a patient in need thereof; and a debris capture device for placement within the ophthalmic vasculature to capture artherectomy debris.
2) A method of treating obstruction of the ophthalmic artery, comprising the steps of: inducing retrograde flow in the ophthalmic vasculature by applying a mechanical force against the front of the eye to increase Intraocular Pressure (IOP) sufficient to temporarily stop antegrade blood flow in the ophthalmic vasculature at the back of the eye; performing an atherectomy upon the ophthalmic artery of a patient in need thereof during retrograde blood flow; and deploying a debris capture device within the ophthalmic vasculature to capture atherectomy debris, wherein the retrograde flow blocks the debris from the atherectomy from flowing downstream and causing an ischemic event.
3) A tissue removal device for treating obstruction of the ophthalmic artery, comprising: a percutaneously delivered tapered corewire ranging in diameter from about 0.19 mm to about 0.88 mm, the corewire disposed within a delivery sheath, said corewire having a tissue cutting element at or near a distal end, said corewire having an integral inflatable balloon section at the distal end as a protective element, and said corewire having an atraumatic tip.
4) A method of use of a shaped tip guidewire, a straight tip guidewire and a guiding catheter, comprising the steps in which the straight tip guidewire is used alone, or in conjunction with the guiding catheter to access the OA from the ICA, once the OA has been cannulated, the shaped tip guidewire is exchanged for the straight tip guidewire for the balance of the procedure.
5) An apparatus for capturing atherectomy debris as it is removed, comprising a single hypo tube cut to contain a combination atherectomy device and distal protection device, wherein the atherectomy device portion fits within a delivery sheath such that the fully expanded diameter is achieved when device is moved out of sheath and into the target anatomy with that fully expanded diameter at 1.4 mm, which compliance to a vessel as small as 0.7 mm., further comprising wherein the atherectomy device portion of the apparatus is expandable, wherein the apparatus has an aspiration device for removal of debris by aspiration via an external sheath.
6) A method for providing treatment for the symptoms related to Wet Age Related Macular Degeneration, comprising the step of removal of stenosis of the OA, thereby restoring normal, or near normal, blood flow to the rear of the eye, including the retina and associated structures.
7) Apparatus that is a single unit, containing a hybrid catheter and flow directed balloon where the OD of single unit being 6-9 french at the thicker, proximal end of the hybrid catheter/balloon with the distal 2-5 CM of the apparatus being 0.12-0.19 mm in diameter of a flow directed guidewire with the final distal portion of the apparatus being 8 to 15 mm of the apparatus being a flow directed balloon, where the flow directed balloon inflates to a maximum of 1.4 mm and a minimum of 0.7 mm, where the balloon is coated with a drug for delivery and compression into the wall of the arterial source with the stenotic lesion.
Description
BRIEF DESCRIPTION OF FIGURES
[0078]
[0079]
[0080]
[0081]
[0082]
[0083]
[0084]
[0085]
[0086]
[0087]
[0088]
[0089]
[0090]
[0091]
[0092]
[0093]
[0094]
[0095]
[0096]
[0097]
[0098]
DETAILED DESCRIPTION OF THE INVENTION
[0099] Without being limited to any specific theory, the invention is based on the premise that the primary causative effect for Wet Age-Related Macular Degeneration (WAMD), glaucoma and diabetic retinopathy is occlusion of the Ophthalmic Artery (OA) such that normal blood flow is restricted (ischemia) to the rear of the eye. As a result of this ischemia, hypoxia (resulting in neovascularization) is induced in these structures and vision eventually devolves into a dysfunctional retina (WAMD). From this, we have identified two designs that may be used to provide a treatment methodology for WAMD. Several variations are detailed later in this specification. These include, 1) a device(s) for performing interventional work in the ophthalmic artery and surrounding structures to restore/increase vascular blood flow and, 2) a device for selectively inducing retrograde blood flow in the retinal vasculature via manipulation for intraocular pressure (IOP).
[0100] Interventional Device
[0101] The interventional device is designed to gain access to and deliver direct mechanical and/or drug therapy to a specific location of the anatomy. While the following examples specifically detail the necessary components for a particular ophthalmic artery (OA) application, this technology may be used in any anatomical location in which removal of material is desired in a luminal environment. This environment may be vascular or not and may be used in any tubal, luminal or other similar anatomical structure where removal of material is desired. As such, the invention can be scaled, modified or constructed such that it can provide therapy for a specific luminal anatomical location/need. The general inventive device design is based on a central wire, hypotube, coil, balloon or combination thereof. The inventive device is made of stainless, nitinol, polymer, other materials or a combination thereof and designed to accommodate specific approaches (carotid, subclavian, femoral, endoscopic or laparoscopic). For the example given, entrance into the body is provided by a vascular access element which may be typical, or may be designed specifically for use with the inventive device (ie: catheter sheath introducer or equivalent). The inventive device fits within a sheath, which is designed to provide a protective element for the device as well as to prevent vessel trauma during delivery to the target site. The distal portion includes the ability to provide distal protection in the OA, as well as an element to provide diametric interference. This area of diametric interference is designed to interface with the target vessel segment (eg; lesion) such that specific and deliberate manipulation provides for the ability to selectively remove material from the lesion site. The diametric interference element also provides for the ability to compress such that it fits within the device sheath to provide a minimal diametric dimension. This diametric portion is also referred to as an interventional element. Once the device is placed at the target anatomy, the interventional element is positioned such that it is outside the sheath and it conformally fits the inner diameter of the target anatomy. The interventional element also contains a design element that allows for tissue removal when manipulated in a specific manner. That manner includes manual rotation, manual push/pull, mechanical rotation, mechanical push/pull, site specific drug delivery or a combination of some or all of those. Additionally, the tissue removal device and conforming element is optionally different devices, two devices or different segments of the same device. Once material removal is complete, the interventional element is pulled into the sheath, along with the distal protection portion (equipped) of the device and the entire assembly removed. It is also possible to remove the interventional element for cleaning and to replace and continue. Furthermore, this device is able to deliver drug therapy directly to the area of intervention. For example, delivery of a pharmaceutical compound to reduce the rate of restenosis may be possible as well as a variety of other pharmaceutical compounds. The device is also constructed such that it is able to provide interventional therapy in the form of energy delivery. This includes, but is not limited to, laser, ultrasound, cryogenic, radiofrequency (RF) and/or other energies or combination thereof. Additionally, there is also the provision for the ability to provide direct optical viewing of the target site prior to, during and after administration of therapy. There is an ability to combine multiple drug therapies for a single condition or multiple conditions. For example, Sirolimus for antiproliferative effect post angioplasty. In addition to this or separate from this, a statin may be included and eluted as lipid like deposits called drusen can be concomitant to Wet AMD. It is presumed that the slow elution of a statin would reduce the size and number of drusen deposits and there by improve eyesight.
[0102] Interventional DeviceCommon Device Elements: [0103] 1. Ability to visualize under fluoroscopy [0104] 2. Preferred internal carotid access (can be done via subclavian or femoral) [0105] 3. Distal protection element in the internal carotid artery (ICA) [0106] 4. Distal protection element in the Ophthalmic Artery [0107] 5. Works in OA diameter ranges between 0.7 to 1.4 mmderived by atmospheric pressure applied to the conformal element [0108] 6. Working length for OA estimated to be about 15 inches, further definitions included [0109] 7. Approaches other than ICA also included [0110] 8. Ability to remove material from the OA and transport out of the vasculature [0111] 9. Ability to induce retrograde flow, either continuously, or on demand for specific time periods. [0112] 10. May use of a guiding catheter to cannulate the OA from the ICA (combination of GC features with sheath to have an all in one)
[0113] Interventional DeviceSingular Elements (Specific to a Particular Design): [0114] 1. Distal OA protection as an integral element of the device [0115] 2. Distal OA protection as a separately placed/removed device [0116] 3. Distal CA protection as an integral element of the device [0117] 4. Distal CA protection as a separately placed/removed device [0118] 5. Distal ICA protection as a integral placed/removed device [0119] 6. Distal ICA protection as a separately placed/removed device. [0120] 7. Ability to deliver an RF element for therapy [0121] 8. Ability to deliver a laser element for therapy [0122] 9. Ability to deliver an ultrasound element for therapy [0123] 10. Ability to deliver a cryogenic element for therapy [0124] 11. Ability to deliver drugs via infusion [0125] 12. Ability to deliver drugs via injection (bolusTPA) [0126] 13. Drug delivery capability before, during and after material removal [0127] 14. Ability to deliver drugs via micro needles
[0128] IA. Interventional DeviceSpecific Examples: Solid Core Wire Based
[0129]
[0136]
[0137]
[0138] Generally, the overall length of the device is optimized for the anatomical location and approach. In a preferred example, for use within the OA, an overall length of about 160 cm or about 15.00 inches for the device would be used in conjunction with an appropriately designed sheath. The maximum overall diameter of the sheath would be in the 1.0 mm range (after inflation), with the cutting and distal protection elements offering a conformal fit capability in the deployed range of between 0.7 mm to 1.4 mm as dictated by the specific dimensions of the OA and the lesion site. Of course, these overall length and diametric dimensions would be adjusted based on the specific applications and is contemplated as within the scope of the invention. In addition, the specific material composition, formulation and manufacturing parameters of material used would be refined to address the specific application and is contemplated as within the scope of the invention. This dimensional information applies to all of the designs disclosed. In one preferred example, the lesion crossing profile of this device is less than 0.2 mm. A range of appropriate profile dimensions is contemplated as within the scope of the invention.
[0139] A. Interventional DeviceSpecific Examples: Plain CoreNon Aspiration Core
[0140] The design in
[0146] This inventive subject matter of
[0147] It should also be noted that the corewire based design may include elements that are much simpler in design than illustrated in the sketch above. These designs could include a wire with a specific drawn profile that is inserted into the anatomy such that movement of the wire would allow an interface between the profile of the corewire and the anatomy to facilitate lesion material removal. These particular designs could include 1) a straight as drawn wire, 2) an as drawn wire with a twist or 3) a selective combination of the two.
[0148]
[0149]
[0150] B. Interventional DeviceHypotube Based
[0151] Integral elementsThe design in
TABLE-US-00001 1. Central guidewire 2. Delivery sheath 3. Hollow tube 4. Cutting element 5. Distal protection element 6. Abrasives
[0152]
[0153] An alternative version of this design would be a hypotube version with cutting and distal protection elements mounted on the hypotube. There would also be a provision for an element that would be positioned in the lumen after removal of the guidewire. This element would serve to deliver fluid for flushing. In this example, aspiration could be accomplished by applying suction to the proximal hypotube such that fluid is removed as well as debris while flushing is activated. While these inventions are not sketched, this document discloses such configuration). A guidewire (1) extends down the inner lumen of the hypotube to provide a means for navigating the anatomy. Upon placement within the target anatomy, the guidewire is removed and the sheath is pulled back, deploying the cutting and distal protection elements. Deployment of the distal elements is controlled by selective manufacturing processes which preferentially train the elements to behave in a certain fashion such that they exhibit a condition known as shape memory. This shape memory is exhibited by the hypotube when it is in an unrestrained position. Abrasives (6) mounted, coated or integral with the cutting element may be designed to facilitate material removal and shaping of the lesion.
[0154]
[0155]
[0156] IC. Interventional DevicePolymer Based Tube
[0157]
[0158]
[0159] ID. Interventional Device
[0160]
[0161] E. Interventional Device
[0162]
[0163] IF. Interventional DeviceBalloon Based
[0164]
[0165]
[0166]
[0167] IG. Interventional DeviceOphthalmic Artery Access Element
[0168]
[0169] IH. Interventional DeviceFlow Directed 1
[0170]
[0171] II. Interventional DeviceFlow Directed 2
[0172]
[0173] IJ. IOP DeviceGeneral Description
[0174]
[0175] Use of the device elements as detailed above will allow for the physician to induce retrograde vascular flow (for up to 3 minutes at a time) such that when the interventional device is used, the risk for retinal vasculature embolism is reduced. It is known that at a minimum retrograde flow in the central retinal artery can be maintained for antithrombotic protection and possibly the ciliary arteries. With pressure put on the front of the eye, the blood volume of the choroid layers can be forced back, through the central retinal artery, ciliary arteries and possibly lacrimal arteries.
[0176]
[0177]
[0178]
[0179] The references recited herein are incorporated herein in their entirety, particularly as they relate to teaching the level of ordinary skill in this art and for any disclosure necessary for the commoner understanding of the subject matter of the claimed invention. It will be clear to a person of ordinary skill in the art that the above embodiments may be altered or that insubstantial changes may be made without departing from the scope of the invention. Accordingly, the scope of the invention is determined by the scope of the following claims and their equitable Equivalents.